Results for:(123 found)
Apr 2, 2013 8:57AM on Top StocksBy Jim Cramer

Even as medical insurers react positively to news, other economically sensitive sectors are under attack.

Mar 14, 2013 12:58PM on Top StocksBy John Reese

If the market's recent rise has you nervous, switching to more defensive investments may be a better course of action than fleeing the market altogether.

Mar 14, 2013 9:43AM on Top StocksBy Benzinga

Some major branded drugs will lose patent protection, and market share along with it, this year.

Mar 13, 2013 9:18AM on Top StocksBy Jim Cramer

Congrats, market, on 8 straight up days. But 9? The last time we had a winning streak like that was last century.

Mar 4, 2013 1:00PM on Top StocksBy MSN Money Partner

Bristol-Myers is downgraded to 'neutral,' and Gap is initiated with an 'underperform.'

Feb 25, 2013 10:56AM on Top StocksBy Stock Traders Daily

The biotech was rumored to be a takeover target but aims to be a buyer instead.

Feb 20, 2013 2:44PM on Top StocksBy Anthony Mirhaydari

Evidence suggests that, despite a lofty stock market, the world economy is already shrinking again.

Feb 13, 2013 4:46AM on Top StocksBy Gene Marcial

This biotech behemoth's appeal is its combined value-and-growth stock characteristics.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More